LEADER 00913nam0-2200313---450- 001 990009327790403321 005 20110311181830.0 035 $a000932779 035 $aFED01000932779 035 $a(Aleph)000932779FED01 035 $a000932779 100 $a20110309d1941----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $a--------001yy 200 1 $a<>theory of organic chemistry$ean advanced course$fby Gerald E. K. Branch and Melvin Calvin 210 $aNew York$cPrentice-Hall$dc1941 215 $aXIX, 523 p.$cill.$d24 cm. 225 1 $aPrentice-Hall chemistry series 676 $a547.1 700 1$aBranch,$bGerald E. K.$0510360 701 1$aCalvin,$bMelvin$090260 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009327790403321 952 $aDCH-070-10$b5908$fDCH 959 $aDCH 996 $aTheory of organic chemistry$9766010 997 $aUNINA LEADER 00721nam0-2200241 --450 001 9910635598003321 005 20230111111209.0 100 $a20230111d1911----kmuy0itay5050 ba 101 0 $ager 102 $aDE 105 $a 001yy 200 1 $a<>Form des Rechts$eEin Beitrag zur allgemeinen Lehre vom System des Burgerlichen Gesetzbuchs ...$fvon A. Sturm 210 $aHannover$cHelwingsche Verlagsbuchhandlung$d1911 215 $aVIII, 189 p.$d24 cm 676 $a340$v23$zita 700 1$aSturm,$bA.$01272633 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a9910635598003321 952 $aXI F 16 Z$b3063$fFGBC 959 $aFGBC 996 $aForm des Rechts$92997611 997 $aUNINA LEADER 02941oam 2200457 450 001 9910136407603321 005 20230621135800.0 010 $a9782889193325 (ebook) 035 $a(CKB)3710000000612036 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45512 035 $a(EXLCZ)993710000000612036 100 $a20191103c2014uuuu uu | 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug-diagnostics co-development in oncology$b[electronic resource] /$ftopic editor Jan Trøst Jørgensen 210 $cFrontiers Media SA$d2014 210 1$aFrance :$cFrontiers Media SA,$d2014 215 $a1 online resource (111 pages) $ccolour illustrations, charts 225 1 $aFrontiers Research Topics 320 $aIncludes bibliographical references. 330 $aThe idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970?s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest?, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. 606 $aOncology 610 $aIHC 610 $afish 610 $aprecision medicine 610 $aNGS 610 $aDrug-diagnostic co-development 610 $acompanion diagnostics 610 $aoncology 610 $apersonalized medicine 615 0$aOncology. 676 $a615.1/9 700 $aJan Trost Jorgensen$4auth$01367185 702 $aJørgensen$b Jan Trøst 801 0$bUkMaJRU 912 $a9910136407603321 996 $aDrug-diagnostics co-development in oncology$93389914 997 $aUNINA